Biogen is awaiting the Food and Drug Administration’s decision regarding its Alzheimer’s disease drug, aducanumab. However, mixed data regarding the drug’s efficacy make approval far from certain. The Institute for Clinical and Economic Review (ICER) noted it had extended its drug assessment timeline. Should the drug prove effective, Biogen has already located 600 healthcare sites that will implement the drug. It expects high demand.
“The FDA’s verdict is far from certain. The data supporting aducanumab are complex and controversial. Alzheimer’s experts remain torn on whether the drug actually improves patients’ lives. Even the FDA’s internal staff are divided about the prospect of approval.” Read more here.
(Source: Jacob Bell, BioPharma Dive, 4/22/21)